- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.07. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| CREATIVE MEDICAL TECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 01.07. | Creative Medical gibt Update zur Geschäftsentwicklung: Fortschritte bei Zelltherapie und Biodefense-Programmen | 1 | Investing.com Deutsch | ||
| 01.07. | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Issues Mid-Year Update | 354 | GlobeNewswire (Europe) | PHOENIX, July 01, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative... ► Artikel lesen | |
| 30.06. | Creative Medical secures $4.5M through warrant exercise deal | 1 | Investing.com | ||
| 30.06. | Creative Medical sichert sich 4,5 Mio. US-Dollar durch Vereinbarung zur Optionsschein-Ausübung | 2 | Investing.com Deutsch | ||
| 30.06. | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.5 Million Gross Proceeds | 1 | GlobeNewswire (USA) | ||
| 25.06. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 22.06. | FDA genehmigt Studienerweiterung für Rückenschmerztherapie von Creative Medical | 3 | Investing.com Deutsch | ||
| 22.06. | FDA clears Creative Medical trial expansion for back pain therapy | 1 | Investing.com | ||
| 22.06. | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain | 305 | GlobeNewswire (Europe) | PHOENIX, June 22, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative... ► Artikel lesen | |
| 16.06. | Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards | 1 | GlobeNewswire (USA) | ||
| 08.05. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 28.04. | Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies | 1 | GlobeNewswire (USA) | ||
| 24.04. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 10-K/A, Annual Report | - | SEC Filings | ||
| 20.03. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 10-K, Annual Report | 2 | SEC Filings | ||
| 10.02. | Creative Medical receives WHO designation for second cell therapy | 3 | Investing.com | ||
| 10.02. | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline | 2 | GlobeNewswire (USA) | ||
| 13.01. | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain | 375 | GlobeNewswire (Europe) | PHOENIX, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative... ► Artikel lesen | |
| 06.01. | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative | 244 | GlobeNewswire (Europe) | PHOENIX, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative... ► Artikel lesen | |
| 17.12.25 | Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point | 250 | GlobeNewswire (Europe) | PHOENIX, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 36,370 | +0,90 % | PTA-PVR: QIAGEN N.V.: Veröffentlichung nach § 40 Abs. 1 WpHG | DJ PTA-PVR: QIAGEN N.V.: Veröffentlichung nach § 40 Abs. 1 WpHG
Veröffentlichung gem. -- 40 Abs. 1 WpHG
QIAGEN N.V.: Veröffentlichung nach -- 40 Abs. 1 WpHG
Venlo (pta000/29.07.2026/22:05... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,15 | -0,03 % | AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates | ||
| VERA THERAPEUTICS | 29,970 | +0,07 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 59,30 | -2,96 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| DYNE THERAPEUTICS | 26,410 | +1,69 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights | - Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 - - Completed enrollment... ► Artikel lesen | |
| TYRA BIOSCIENCES | 26,280 | -19,21 % | Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights | - Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) -
- Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in... ► Artikel lesen | |
| COGENT BIOSCIENCES | 42,380 | -1,07 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| VERADERMICS | 112,08 | +4,53 % | Weekly Buzz: Novartis, Merck & Co. Win FDA Nod; Eli Lilly Snaps Up AtaiBeckley; Veradermics Shines On Hair Loss Data | BASEL (dpa-AFX) - This week, the healthcare sector saw multiple U.S FDA and European Commission approvals, strategic licensing and M&A activity, as well as pivotal clinical trial readouts and... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,270 | -3,81 % | Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) | Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients... ► Artikel lesen | |
| ERASCA | 18,650 | +1,52 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| CG ONCOLOGY | 72,27 | +1,21 % | CG Oncology stock maintained at Buy by H.C. Wainwright on trial data | ||
| RECURSION PHARMACEUTICALS | 3,155 | -4,68 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program | Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated... ► Artikel lesen | |
| EVOTEC | 3,430 | -0,46 % | Wirkstoffe, Zukäufe, Aufspaltungen: Werden Bayer, Novo Nordisk, BioNxt oder Evotec zu Top-Übernahme-Kandidaten? | Nach einer jahrelangen Konsolidierung fragen sich Investoren: Geht es auch mal wieder aufwärts? Der globale LifeScience-Sektor steht auch im Jahr 2026 vor einer massiven Konsolidierungswelle, da etablierte... ► Artikel lesen | |
| CABALETTA BIO | 2,755 | -0,54 % | Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress | 83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registrational primary endpoint; all these patients maintained their response off immunomodulators through... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 26,830 | +3,07 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen |
CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,022 (-3,35 %) liegt der Kurs bei 0,634 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.